Mecacci Federico, Carignani Lucia, Cioni Riccardo, Bartoli Elisa, Parretti Elena, La Torre Pasquale, Scarselli Gianfranco, Mello Giorgio
Department of Gynaecology, Perinatology and Human Reproduction, University of Florence, Viale Morgagni 85, I-50134 Florence, Italy.
Eur J Obstet Gynecol Reprod Biol. 2003 Nov 10;111(1):19-24. doi: 10.1016/s0301-2115(03)00157-x.
To compare maternal glucose levels and neonatal outcome, achieved in women with gestational diabetes (GDM) receiving either regular insulin or insulin lispro, with those of a control group of non-diabetic pregnant women.
We enrolled 49 pregnant women with GDM, randomly allocated to the treatment with either insulin lispro (n=25) or regular insulin (n=24), and 50 pregnant women with normal GCT, matched for age, parity, pre-pregnancy weight and BMI, who formed the control group. All the women were caucasian, non-obese, with a singleton pregnancy and delivered term live born infants. Women of both groups were requested to perform a blood glucose profile (consisting of nine determinations: fasting/pre-prandial, 1 and 2h post-prandial) every week from the time of diagnosis to 38 weeks (study subgroups) or every 2 weeks from 28 to 38 weeks' gestation (control group).
Overall pre-prandial blood glucose values in diabetic women were significantly higher than those of controls; at the 1h post-prandial time point, blood glucose values of GDM women receiving insulin lispro were similar to those of controls, whereas in the regular group they were significantly higher. Overall, both the lispro and regular insulin obtained optimal metabolic control at the 2h post-prandial time point, although near-normal blood glucose levels 2h after lunch could be observed only in the lispro group. There were no statistically significant differences between the groups in neonatal outcome and anthropometric characteristics; however, the rate of infants with a cranial-thoracic circumference (CC/CT) ratio between the 10th and the 25th percentile was significantly higher in the group treated with regular insulin in comparison to the lispro and control groups.
Fasting/pre-prandial and 1h post-prandial maternal blood glucose levels in non-diabetic pregnant women fell well below the currently accepted criteria of glycemic normality in diabetic pregnancies. In women with GDM, the use of insulin lispro enabled the attainment of near-normal glucose levels at the 1h post-prandial time point and was associated with normal anthropometric characteristics; the use of regular insulin was not able to blunt the 1h peak post-prandial response to a near-normal extent and resulted in infants with a tendency toward the disproportionate growth. Insulin lispro can be regarded as a valuable option for the treatment of gestational diabetes.
比较妊娠期糖尿病(GDM)女性接受赖脯胰岛素或常规胰岛素治疗后的母体血糖水平及新生儿结局,并与非糖尿病孕妇对照组进行对比。
我们招募了49例GDM孕妇,随机分为赖脯胰岛素治疗组(n = 25)或常规胰岛素治疗组(n = 24),以及50例葡萄糖耐量试验(GCT)正常的孕妇作为对照组,对照组孕妇在年龄、产次、孕前体重和体重指数方面进行匹配。所有女性均为白种人,非肥胖,单胎妊娠,足月分娩活产婴儿。两组女性均被要求从诊断时起至38周(研究亚组)每周进行一次血糖监测(包括九次测定:空腹/餐前、餐后1小时和2小时),或从妊娠28周至38周每2周进行一次血糖监测(对照组)。
糖尿病女性的总体餐前血糖值显著高于对照组;在餐后1小时时间点,接受赖脯胰岛素治疗的GDM女性血糖值与对照组相似,而常规胰岛素组则显著更高。总体而言,赖脯胰岛素和常规胰岛素在餐后2小时时间点均获得了最佳代谢控制,尽管仅在赖脯胰岛素组观察到午餐后2小时血糖水平接近正常。两组在新生儿结局和人体测量特征方面无统计学显著差异;然而,常规胰岛素治疗组婴儿的头胸围(CC/CT)比值在第10至第25百分位数之间的比例显著高于赖脯胰岛素组和对照组。
非糖尿病孕妇的空腹/餐前及餐后1小时母体血糖水平远低于目前糖尿病妊娠所接受的血糖正常标准。在GDM女性中,使用赖脯胰岛素可使餐后1小时血糖水平接近正常,并与正常人体测量特征相关;使用常规胰岛素不能在接近正常的程度上抑制餐后1小时的血糖峰值反应,并导致婴儿有生长比例失调的倾向。赖脯胰岛素可被视为治疗妊娠期糖尿病的一种有价值的选择。